Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Monotherapy
100%
Combination Therapy
100%
Trial Protocol
100%
Senicapoc
100%
Perampanel
100%
Window of Opportunity Clinical Trial
100%
Newly Diagnosed Glioblastoma
100%
Maximum Tolerated Dose
50%
Glioblastoma
50%
Tumor
33%
Window of Opportunity
33%
Beta-blockers
16%
Denmark
16%
University Hospital
16%
Randomized Clinical Trial
16%
Trial Registration
16%
Adult Patients
16%
Treatment Strategy
16%
Intolerance
16%
Non-competitive
16%
Pharmacokinetics
16%
Receptor Activation
16%
Molecular Genetics
16%
Before Surgery
16%
Cerebrospinal Fluid
16%
Progression-free Survival
16%
In Cancer
16%
Cancer Cells
16%
Aarhus
16%
Biological Effects
16%
Tumor Microenvironment
16%
Median Overall Survival
16%
Standard of Care
16%
Primary Brain Tumor
16%
Dose Escalation
16%
Safety Impact
16%
Drug Action
16%
Synapse
16%
Tumor Volume Change
16%
Calcium Signaling
16%
Dismal Prognosis
16%
Targeting Strategies
16%
Cell Therapy
16%
Drug Penetration
16%
Safety Parameters
16%
Cell Networks
16%
Objective Response Rate
16%
Therapy Resistance
16%
Network Target
16%
AMPA Receptor (AMPAR)
16%
Tumor Profile
16%
Adjuvant Radiochemotherapy
16%
AMPA Receptor Antagonist
16%
Neurosurgery Department
16%
KCa3.1 Channel
16%
Tumor Drugs
16%
Glioma Invasion
16%
Network Centric Therapy
16%
Cancer Neuroscience
16%
Aarhus University
16%
Patient Will
16%
Safety Pharmacokinetics
16%
Guided Therapy
16%
Pharmacokinetic Activity
16%
Translational Analysis
16%
Glioma Proliferation
16%
Juul
16%
Dual Network
16%
Network Resilience
16%
Boulevard
16%
Genetic Tumor
16%
Tumor Cell Network
16%
Network Resistance
16%
Excitatory Neurons
16%
Parameter-free
16%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Combination Therapy
100%
Clinical Trial
100%
Glioblastoma
100%
Senicapoc
100%
Perampanel
100%
Maximum Tolerated Dose
50%
Malignant Neoplasm
33%
Pharmacokinetics
33%
Randomized Clinical Trial
16%
Overall Survival
16%
Progression Free Survival
16%
Preclinical Study
16%
Tumor Microenvironment
16%
Intracranial Tumor
16%
Therapy Resistance
16%
AMPA Receptor
16%
Glioma
16%
AMPA Receptor Antagonist
16%
Low Drug Dose
16%